Abstract
Pharmacoepidemiology is the application of epidemiological principles and methods to the study of drug effects in human populations. The goal of this discipline is to characterize, control and predict the effects and uses of pharmacological treatment modalities.
Pharmacoepidemiology is also concerned with the economic impact and health benefits of unintended drug effects. The increasing importance of pharmacoepidemiology has been created by the need to develop a more accurate portrait of how drugs are used in the general population. Sophisticated and potent drug carefully controlled clinical trials of Phases I, II and III. Case-control and cohort studies, which allow scientists to evaluate the effects of patient variables on clinical outcomes, provide a wealth of information regarding the study of unexpected drug effects, drug utilization, treatment costs and the individualization of therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Strom BL. What is pharmacoepidemiology? In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:3–12.
Hartzema AG, Martini N. Pharmacoepidemiology: the role of the clinical pharmacist. Kalamazoo: Upjohn Company, 1991.
Spilker B. Safety profiles of new drugs at the time of initial marketing. In: Hartzema AG, Porta MS, Tilson HH, editors. Pharmacoepidemiology: an introduction. 2nd ed. Cincinnati: Harvey Whitney, 1991:35.
Strom BL. Study designs available for pharmacoepidemiology studies. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:13–26.
Strom BL. Sample size considerations for pharmacoepidemiologic studies. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:27–37.
Strom BL. When should one perform pharmacoepidemiologic studies? In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:39–47.
Lawson DH, Beard K. Intensive hospital-based cohort studies. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:135–48.
Stergachis A. Group health cooperative of Puget Sound. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:149.
Carson JL, Strom BL, Maislin G. Screening for unknown effects of newly marketed drugs. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:295.
Strom BL, Melmon KL. The use of pharmacoepidemiology to study beneficial drug effects. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989: 307.
Lee D, Bergman U. Studies of drug utilization. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:259–74.
Eisenberg JM, Glick H, Koffer H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:325–50.
Smith CR, Moore RD. Using epidemiologic methods to individualize drug therapy. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:351–60.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wertheimer, A.I., Andrews, K.B. An overview of pharmacoepidemiology. Pharm World Sci 17, 61–66 (1995). https://doi.org/10.1007/BF01875433
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01875433